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Abstract
Leishmaniasis is endemic in Europe and the prevalence of latent infection in the Mediterranean region is high. Reports describing oppor-
tunistic leishmaniasis in European patients treated with tumor necrosis factor (TNF) alpha antagonist drugs are rapidly accumulating.
For other granulomatous infections, risk of opportunistic disease varies by mode of TNF-alpha antagonism. This study explores whether
this may also be the case for leishmaniasis. We ascertained the relative frequency of exposure to different TNF antagonist drugs among
published cases of opportunistic leishmaniasis in Europe and compared this with the prescription of these drugs in Europe. We found
that risk of opportunistic leishmaniasis is higher in patients receiving anti-TNF monoclonal antibodies (infliximab or adalimumab) com-
pared with patients treated with the TNF-receptor construct etanercept. Clinicians may want to consider these observations, which
suggest that etanercept should be favoured over anti-TNF monoclonal antibodies in individuals living in or visiting areas endemic for
leishmaniasis until evidence from prospective research is available. A European adverse event reporting system is required to identify
rare opportunistic infections associated with immunosuppressive and immunomodulatory biotherapies.
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Introduction
The clinical spectrum of leishmaniasis depends to a large
extent on the host’s immune response. Immunodeficiency, in
particular disturbances of the type 1 helper T cell-mediated
(Th1) immune response, can impair containment of these
intracellular parasites and thus promote manifestation and
progression of the disease, with potentially fatal conse-
quences. Tumor necrosis factor (TNF) alpha is a key cyto-
kine involved in Th1-dependent granuloma formation,
explaining why patients treated with TNF antagonists have
an increased risk of granulomatous infectious diseases.
This increase in risk varies markedly between the different
inhibitors currently in use. An analysis of cases from adverse
event reporting systems in the USA and Europe revealed
that antagonism with anti-TNF monoclonal antibodies (the
active compound of infliximab and adalimumab) is associated
with a markedly higher risk of tuberculosis reactivation than
treatment with the TNF-alpha receptor construct etanercept
[1,2]. Similar associations have been reported for histoplas-
mosis, listeriosis, candidiasis, nocardiosis, coccidioidomycosis
and non-tuberculous mycobacteria, but not for opportunistic
leishmaniasis, most probably because leishmaniasis is not
endemic in the USA, the region with the largest population
covered by a single adverse event reporting system [1].
Europe, by contrast, is endemic for leishmaniasis and has
seen an increasing number of opportunistic leishmaniasis
cases in patients treated with TNF-alpha antagonists as this
highly effective treatment has become more common in
recent years [3–19]. Leishmaniasis as a potential side-effect
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of TNF antagonist treatment poses a growing therapeutic
dilemma in regions with high prevalence of latent leishmania-
sis infection, such as the Mediterranean region [20–22]. To
prevent serious and potentially fatal cases of leishmaniasis,
there is a need to identify risk factors for this infection in
patients treated with TNF-alpha antagonist drugs. In particu-
lar, if there was a similar variation in risk of infection by
mode of TNF-alpha antagonism as described for other granu-
lomatous infections, this would have a major impact on
treatment decisions in patients with autoimmune disease liv-
ing in areas endemic for leishmaniasis.
The European guidelines on pharmacovigilance require
pharmaceutical companies to conduct a regular search of the
published literature for reports that describe adverse out-
comes in association with the use of their medicinal products
[23]. Despite this mandatory exercise and similar findings for
other granulomatous infections, the possible variation in risk
of leishmaniasis by type of TNF-alpha antagonism has not
been widely discussed so far. This lack of attention may be a
consequence of the overall low incidence of opportunistic
leishmaniasis, the resulting scarcity of such reports (both in
the literature and through adverse reporting systems), and
the fact that pharmaceutical companies collect and report
information on different marketed compounds separately to
the competent regulatory authorities. To address these and
other shortcomings in monitoring rare but serious adverse
events, professional societies in some European countries
have launched registries with the aim of monitoring the
safety of TNF-alpha antagonist drugs more closely [24,25].
However, using this approach, the French registry, for
instance, could only detect two cases of opportunistic leish-
maniasis over a 3-year period, illustrating that collecting
reports on a national level is unlikely to provide enough
cases to study differences in drug-specific risk for leishmania-
sis among patients receiving anti-TNF therapy in the coming
years [25].
As an alternative approach, we reviewed the published
case reports on opportunistic leishmaniasis associated with
anti-TNF therapies from Europe and gathered information
on the use of these drugs in those European countries that
reported opportunistic leishmaniasis in the published litera-
ture, in order to investigate whether risk of opportunistic
leishmaniasis infection differs by type of anti-TNF therapy.
Methods
We retrieved reports of leishmaniasis in patients treated
with TNF-alpha antagonists from the PubMed database using
the MESH terms ‘TNFR-Fc fusion protein’ OR ‘adalimumab’
OR ‘infliximab’ and subsequently used AND to link the result
with that of a search using the MESH terms ‘leishmaniasis’
OR ‘infection’. Furthermore, we screened the references of
these reports for publications with similar content. We then
recorded type and duration of anti-TNF therapy prior to
onset of leishmaniasis and restricted the analysis to cases
reported from Europe. To obtain estimates for the relative
frequency with which different TNF antagonists are pre-
scribed in Europe (i.e. among the source population of cases)
we used published data from Italy [26–29] and Germany
[30,31] on defined daily doses of TNF-alpha antagonists pre-
scribed in the years 2006–2009. For the remaining countries
that reported cases of opportunistic leishmaniasis in associa-
tion with TNF-alpha antagonism and for which detailed pre-
scription data were not available (Italy, Spain and Greece),
data from large studies [32] or adverse events registries
[2,24] were used. Based on this information, we calculated
the odds of exposure to TNF neutralization with antibodies
(adalimumab and infliximab) vs. TNF neutralization with the
soluble receptor (etanercept) in both the European popula-
tion under anti-TNF treatment and in published case
patients. We then calculated the odds ratio (OR) to obtain
an estimate of the relative risk of leishmaniasis by mode of
TNF antagonism. Given that leishmaniasis is a relatively rare
disease, the OR can serve as an estimate of the risk ratio.
Finally, to evaluate the role of chance, we tested the null
hypothesis of no difference in the proportionate exposure to
either type of TNF antagonist therapy between published
cases of opportunistic leishmaniasis and the population of
anti-TNF-treated patients, using exact binomial probabilities.
Results
Overall, we identified 19 cases of opportunistic leishmaniasis
associated with anti-TNF therapy. Only one of these had
occurred outside Europe and was thus excluded from the
analysis [33]. Table 1 summarizes all published cases of
opportunistic leishmaniasis associated with anti-TNF therapy.
The number of case reports increased drastically over time,
with more than two-thirds published in the last 2 years. Two
cases were described in individuals from non-endemic
regions of Europe with a recent travel history to Spain and
Algeria [9,12], one was observed in an immigrant from Eri-
trea living in Germany with a recent travel history to his
country of birth [18], and one case was reported in an immi-
grant from Algeria living in the south of France [15]. The
remaining 14 subjects represent autochthonous cases of
leishmaniasis. The average time from start of anti-TNF ther-
apy to onset of leishmaniasis was 17.5 months, with a median
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of 18 months. In seven subjects, anti-TNF therapy was
recommenced after successful treatment of leishmaniasis:
three subjects were switched from infliximab to etanercept
[4,8,18], two were continued on adalimumab [9,10; all five
remained free of disease. Two patients were continued on
infliximab and experienced recurrent cutaneous [12] and
mucocutaneous [19] leishmaniasis.
Table 2 gives an overview of the prescription patterns of
TNF-alpha antagonists in Italy and Germany from 2006 to
2009 stratified by mode of inhibition. Over this time, the
number of defined daily doses prescribed in Italy nearly dou-
bled from 7 to 13.8 million, and more than doubled in Ger-
many. During the same period, the proportionate use of
anti-TNF monoclonal antibodies compared with the receptor
construct remained relatively stable and was similar in Italy
and Germany, showing a ratio of about 2:1 of monoclonal
antibodies to soluble receptor. Very similar prescription pat-
terns were reported from Greece and Spain (Table 3). Data
from France showed an approximately equal use of receptor
construct and anti-TNF monoclonal antibodies, leading to a
presumed prescription ratio of 1:1.
Among published cases from Europe, 16 patients had
received anti-TNF monoclonal antibodies and only one
patient had been treated with the receptor construct etaner-
cept. The case of a child that had been exposed to both
(11 months of etanercept followed by 12 months of inflix-
imab before manifestation of visceral leishmaniasis [19]) was
excluded from the quantitative analysis. Comparing the ratio
of 16:1 in the remaining cases to a conservative estimate of
the prescription ratio of 2:1 in the source population yields
an approximately 8-fold increased odds of exposure to anti-
TNF monoclonal antibodies vs. etanercept among cases,
which corresponds to an 8-fold increased odds of opportu-
nistic leishmaniasis in patients treated with antibody as
opposed to etanercept. Calculating exact binomial probabili-
ties reveals that such a small number of etanercept-related
cases would be unlikely to occur by chance (p 0.0096) if the
true treatment ratio in patients with opportunistic leishmani-
asis (of TNF-antibody to etanercept) was 2:1.
Discussion
We found that among reported cases of opportunistic leish-
maniasis under TNF-antagonist treatment, 16 had been trea-
ted with antibody and one with etanercept, while
prescription numbers for monoclonal antibodies are only
about twice those of etanercept. This is unlikely to be
explained by chance. We estimated that treatment with anti-
body is associated with approximately 8-fold odds of oppor-T
A
B
L
E
1
.
P
u
b
li
sh
e
d
c
a
se
re
p
o
rt
s
o
f
le
is
h
m
a
n
ia
si
s
a
ss
o
c
ia
te
d
w
it
h
a
n
ti
-T
N
F
-a
lp
h
a
th
e
ra
p
y
b
y
e
n
d
o
f
2
0
1
0
R
e
g
io
n
F
ir
st
a
u
th
o
r
Y
e
a
r
o
f
p
u
b
li
c
a
ti
o
n
S
e
x
,
a
g
e
P
re
se
n
-t
a
ti
o
n
A
n
ti
-T
N
F
tr
e
a
tm
e
n
t
C
o
n
d
it
io
n
C
o
u
n
tr
y
C
o
m
m
e
n
t
T
y
p
e
D
u
ra
ti
o
n
b
e
fo
re
o
n
se
t
o
f
le
is
h
m
a
n
ia
si
s
in
m
o
n
th
s
R
e
st
a
rt
a
ft
e
r
tr
e
a
tm
e
n
t
o
f
le
is
h
m
a
n
ia
si
s
T
y
p
e
D
u
ra
ti
o
n
in
y
e
a
rs
O
f
re
p
o
rt
O
f
a
c
q
u
is
it
io
n
E
u
ro
p
e
R
o
m
an
i-
C
o
st
a
2
0
0
4
M
,
5
5
V
L
In
fl
ix
im
ab
9
N
o
in
fo
rm
at
io
n
P
SA
2
5
Sp
ai
n
Sp
ai
n
–
Fa
b
re
2
0
0
5
F,
5
3
V
L
In
fl
ix
im
ab
7
E
ta
n
e
rc
ep
t
R
A
c.
5
Fr
an
ce
Fr
an
ce
–
B
as
se
tt
i
2
0
0
6
F,
6
9
V
L
A
d
al
im
u
m
ab
2
5
N
o
n
e
R
A
3
0
It
al
y
It
al
y
–
B
ag
al
as
2
0
0
7
F,
6
0
V
L
E
ta
n
er
ce
p
t
N
o
in
fo
rm
at
io
n
N
o
t
ap
p
lic
ab
le
R
A
8
G
re
ec
e
G
re
ec
e
D
ie
d
T
ek
to
n
id
o
u
2
0
0
8
M
,
4
5
V
L
In
fl
ix
im
ab
3
6
N
o
n
e
P
SA
c.
5
G
re
ec
e
G
re
ec
e
–
X
yn
o
s
2
0
0
9
F,
7
1
V
L
In
fl
ix
im
ab
2
4
N
o
in
fo
rm
at
io
n
G
C
A
N
o
in
fo
rm
at
io
n
G
re
ec
e
G
re
ec
e
–
X
yn
o
s
2
0
0
9
M
,
5
5
C
L
In
fl
ix
im
ab
1
2
E
ta
n
e
rc
ep
t
A
SP
7
G
re
ec
e
G
re
ec
e
–
Sc
h
n
e
id
e
r
2
0
0
9
F,
5
1
C
L
A
d
al
im
u
m
ab
2
0
A
d
al
im
u
m
ab
A
SP
4
Fr
an
ce
A
lg
e
ri
a
R
e
ce
n
t
tr
av
e
l
B
al
ta
-C
ru
z
2
0
0
9
F,
5
6
M
C
L
A
d
al
im
u
m
ab
2
6
A
d
al
im
u
m
ab
R
A
1
7
Sp
ai
n
Sp
ai
n
–
D
e
L
e
o
n
ar
d
is
2
0
0
9
M
,
6
3
V
L
In
fl
ix
im
ab
2
4
N
o
in
fo
rm
at
io
n
P
SA
1
6
It
al
y
It
al
y
–
M
u
e
lle
r
2
0
0
9
M
,
3
1
C
L
In
fl
ix
im
ab
4
8
In
fl
ix
im
ab
A
SP
1
7
G
e
rm
an
y
Sp
ai
n
R
e
ce
n
t
tr
av
e
l;
re
cu
rr
e
n
t
C
L
G
ar
ci
a
V
id
al
2
0
0
9
M
,
5
5
V
L
In
fl
ix
im
ab
1
1
N
o
in
fo
rm
at
io
n
E
A
2
5
Sp
ai
n
Sp
ai
n
–
Je
zi
o
rs
ki
2
0
0
9
F,
7
V
L
E
ta
n
er
ce
p
t/
in
fl
ix
im
ab
a
2
3
(1
1
&
1
2
)
In
fl
ix
im
ab
JI
A
3
Fr
an
ce
Fr
an
ce
R
e
cu
rr
e
n
ce
as
M
C
L
K
ri
ti
k
o
s
2
0
1
0
F,
7
7
V
L
In
fl
ix
im
ab
6
N
o
in
fo
rm
at
io
n
R
A
N
o
in
fo
rm
at
io
n
G
re
ec
e
G
re
ec
e
–
H
ak
im
i
2
0
1
0
M
,
5
0
C
L
In
fl
ix
im
ab
7
N
o
n
e
A
SP
2
Fr
an
ce
Fr
an
ce
o
r
A
lg
e
ri
a
B
o
rn
in
A
lg
e
ri
a
M
o
re
n
o
2
0
1
0
F,
7
2
V
L
A
d
al
im
u
m
ab
1
N
o
n
e
R
A
1
5
Sp
ai
n
Sp
ai
n
–
M
o
lt
o
2
0
1
0
M
,
6
0
V
L
A
d
al
im
u
m
ab
1
8
N
o
n
e
R
A
c.
5
Sp
ai
n
Sp
ai
n
–
Z
an
ge
r
2
0
1
1
M
,
3
8
C
L
In
fl
ix
im
ab
0
.5
E
ta
n
e
rc
ep
t
R
A
6
G
e
rm
an
y
E
ri
tr
ea
B
o
rn
in
E
ri
tr
ea
;
re
ce
n
t
tr
av
e
l
O
th
e
r
Fr
an
k
lin
2
0
0
9
F,
4
2
M
C
L
A
d
al
im
u
m
ab
2
–
3
N
o
in
fo
rm
at
io
n
R
A
N
o
in
fo
rm
at
io
n
U
SA
B
ra
zi
l
B
o
rn
in
B
ra
zi
l
V
L
,
vi
sc
e
ra
l
le
is
h
m
an
ia
si
s;
C
L
,
cu
ta
n
e
o
u
s
le
is
h
m
an
ia
si
s;
M
C
L
,
m
u
co
cu
ta
n
e
o
u
s
le
is
h
m
an
ia
si
s;
R
A
,
rh
e
u
m
at
o
id
ar
th
ri
ti
s;
JI
A
,
ju
ve
n
ile
id
io
p
at
h
ic
ar
th
ri
ti
s;
A
SP
,
an
k
yl
o
si
n
g
sp
o
n
d
yl
it
is
;
P
SA
,
p
so
ri
at
ic
ar
th
ri
ti
s;
G
C
A
,
gi
an
t
ce
ll
ar
te
ri
ti
s;
E
A
,
e
n
te
ro
p
at
h
ic
ar
th
ri
ti
s.
a
M
an
ife
st
at
io
n
o
f
V
L
af
te
r
1
1
m
o
n
th
s
o
f
e
ta
n
e
rc
e
p
t
fo
llo
w
e
d
b
y
1
2
m
o
n
th
s
o
f
in
fl
ix
im
ab
.
672 Clinical Microbiology and Infection, Volume 18 Number 7, July 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 670–676
tunistic leishmaniasis. Our results are in line with investiga-
tions that used data from adverse event reporting systems in
the United States and France, reporting that the use of the
anti-TNF monoclonal antibodies, compared with the soluble
receptor construct etanercept, was associated with an 8- to
17-fold increased risk of tuberculosis [1,2]. Similarly, based
on data from the French adverse event registry, a 10- to 17-
fold higher risk of non-tuberculosis opportunistic infections
in patients receiving monoclonal antibody treatment was
reported [25]. The latter study, however, combined patients
with infections of viral and bacterial origin and identified only
two patients with leishmaniasis, thus not allowing any infer-
ences on the variation in risk of opportunistic leishmaniasis
by mode of TNF-antagonism used. The scarcity of opportu-
nistic leishmaniasis reported to this registry demonstrates
that national level data, even in a large endemic country of
Europe such as France, will not provide a sufficient number
of cases to study risk factors for rare adverse events such as
opportunistic leishmaniasis in the coming years. Based on this
we conclude that a European adverse events reporting
system is required to identify associations of TNF-alpha ther-
apies with the occurrence of rare opportunistic infections.
Moreover, the French experience demonstrates that regis-
tries are as prone to under-reporting as publication of cases:
while the French registry had identified two cases of oppor-
tunistic leishmaniasis from 2004 to 2007 [25], we found that
three cases were published from France between 2005 and
2010 (Table 1). With regard to estimating proportionate
drug exposure among patients with autoimmune disease, we
found that the analysis of routine data from Germany and
Italy (Table 2) gave very similar results to data of patients
enrolled in the Spanish registry (Table 3) and that the French
registry also uses routine data to estimate exposure to anti-
TNF therapies [25]. Hence, in the absence of a European
registry, our approach comparing published case reports and
routine data on TNF-alpha antagonist use, with the aim of
investigating whether the risk of opportunistic leishmaniasis
varies by type of therapy is scientifically on a par with the
registry approach and the only quick and efficient way to
inform current clinical decision making.
From a biological point of view, the apparent variation in
risk of leishmaniasis by type of anti-TNF therapy might be
explained by three important differences in the mode of
action of the various compounds. Firstly, anti-TNF monoclo-
nal antibodies bind the mono- and trimeric soluble as well as
the transmembrane form of TNF, whereas etanercept tar-
gets mainly soluble trimeric TNF and interacts with the
transmembrane form with reduced avidity only [34]. Studies
in mice showed that transmembrane TNF but not soluble
TNF is essential to control infection with L. major [35], and
that complete TNF deficiency leads to disseminated and
rapidly fatal disease [36]. Moreover, in vitro experiments
demonstrated that even in the complete absence of soluble
TNF-alpha the capability of macrophages to kill L. donovani
remains unaltered but is drastically reduced after treatment
of macrophages with TNF-alpha antibodies [37]. Our obser-
vation of a lower risk of opportunistic leishmaniasis in
TABLE 3. TNF-alpha inhibitor use in other European countries reporting opportunistic leishmaniasis (in % of patients treated)
Data source [Reference] Sample size
Monoclonal antibody Receptor construct
OddsaAdalimumab (%) Infliximab (%) Sum (%) Etanercept (%)
Greece Studyb [32] n = 663 18 49 67 32 2.1
France Salesc [2] 57 711 py 18 31 49 51 1.0
Spain Registryd [24] n = 5783e 24 45 64 31 2.2
Py, patient years.
aOdds of prescription of monoclonal antibody vs. receptor construct.
bRetrospective university centre based study reviewing files from patients with rheumatic diseases and receiving TNF-alpha antagonists from July 2000 to June 2004.
cMean % of patients treated; estimates of the French national adverse events registry (RATIO), which are based on sales data covering the period from 2004 to 2006 and
were provided by the French regulatory agency for medical products and three pharmaceutical companies.
dSpanish national adverse events registry for biologicals in rheumatic diseases (Biobadaser).
eNumber of patients registered by November 2010 that have received one of the three TNF-alpha antagonists of interest as first treatment.
TABLE 2. TNF-alpha inhibitors prescribed in Italy and Ger-
many from 2006 to 2009 (in million defined daily doses)
Monoclonal antibody Receptor construct
Adalimumab Infliximab Sum Etanercept Total Oddsa
Italyb
2006 1.0 3.0 4.0 3.0 7.0 1.3
2007 1.8 4.2 6.0 3.6 9.6 1.7
2008 2.6 4.8 7.4 4.3 11.7 1.7
2009 3.6 5.1 8.7 5.1 13.8 1.7
Total 9.0 17.1 26.1 16.0 42.1 1.6
Germanyc
2006 0.05 0.08 0.13 0.07 0.20 1.9
2007 0.08 0.09 0.17 0.09 0.26 1.9
2008 0.12 0.12 0.24 0.12 0.36 2.0
2009 0.17 0.15 0.32 0.15 0.47 2.1
Total 0.42 0.44 0.86 0.43 1.29 2.0
aOdds of prescription of monoclonal antibody vs. receptor construct.
bUsing data from national reports [26–29].
cFrom a sample of 1.7 million subjects insured with the Gmu¨nder Ersatzkasse,
adjusted for age and sex using all publicly insured subjects (85% of the German
population) as a reference [30,31].
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patients treated with etanercept is thus biologically plausible
as this compound primarily targets soluble TNF-alpha and
only to a lesser extent transmembrane TNF. Secondly, anti-
TNF monoclonal antibodies can induce apoptosis of mono-
cytes and T-lymphocytes via activation of complement or
antibody-dependent cellular cytotoxicity, whereas etanercept
does not – an observation that might explain the extended
therapeutic spectrum of anti-TNF monoclonal antibodies to
include non-infectious granulomatous conditions such as
Crohn’s disease [38]. At the same time, induction of apopto-
sis could also explain the increased potential of monoclonal
antibodies to disintegrate pathogen-containing granulomata
and thus to reactivate latent infection [39]. Thirdly, consider-
ing that anti-TNF monoclonal antibodies through their multi-
ple binding sites lead to a more complete elimination of TNF
than does the receptor construct, the higher risk of granu-
lomatous infections under antibody therapy may represent a
mere dose–response effect. To date it is unclear to what
extent each of these mechanisms is responsible for the
observed difference in the increase in risk of opportunistic
infections by mode of TNF-alpha antagonism. Nevertheless,
the current body of knowledge on the biology of TNF and
its antagonists, and the known increased risk of developing
other granulomatous infectious diseases while receiving anti-
TNF therapy add external validity to our findings and render
a causal association between mode of TNF antagonism and
risk of opportunistic leishmaniasis a more likely explanation
than chance, bias or confounding.
This study has several limitations. Similarly to cases
retrieved from voluntary adverse event reporting systems
used in comparable studies [1,25], published cases are sub-
ject to under-reporting and thus our analysis is likely to
underestimate the true magnitude of leishmaniasis associated
with anti-TNF-alpha use. The main purpose of our analysis,
however, was to demonstrate a variation in risk of leishmani-
asis according to the mode of TNF antagonism using propor-
tionate exposure among cases compared with the population
of all patients with autoimmune disease receiving anti-TNF
therapy. Hence, only differential under-reporting accounting
for much lower probability of publication of cases treated
with etanercept than cases treated with anti-TNF monoclo-
nal antibodies would render our finding spurious, a scenario
which seems unlikely. In particular, publication bias through
differences in scientific interest with regard to one or the
other TNF-alpha antagonist drug is not a major concern
because all compounds of interest here have more or less
simultaneously received marketing authorization in Europe
and should thus have been of equal interest to authors, edi-
tors and the audience of medical journals over the course of
time.
Further, it is possible that age, differences in the duration
and severity of the autoimmune condition and exposure to
other immunosuppressive compounds may confound the
association between mode of anti-TNF therapy and risk of
leishmaniasis. Unfortunately, the scarcity of cases associated
with etanercept does not allow analysis of the potential influ-
ence of such factors. The magnitude of effect, however,
appears rather too large to be explained by confounding
alone. Moreover, most of the published cases were treated
for rheumatoid arthritis, ankylosing spondylitis and psoriatic
arthritis, for which all three TNF-alpha antagonists are
licensed in Europe and, most importantly, are considered
more or less equally effective [40–42]. Hence, it is unlikely
that choice of TNF-alpha antagonist is systematically associ-
ated with a specific patient subgroup and thus with alterna-
tive risk factors for leishmaniasis such as concomitant use of
other immunosuppressants.
Another concern would be confounding through an asso-
ciation of TNF-alpha antagonist class (antibody vs. etaner-
cept) with the geographical distribution of leishmaniasis in
Europe. In this scenario, a more frequent use of antibody-
based TNF-alpha antagonists in endemic regions would be an
alternative explanation for the observed association with
opportunistic leishmaniasis. This seems rather unlikely, but
to rule it out one would need to analyse prescription pat-
terns with fine geographical resolution.
Finally, the presented study does not lend itself to demon-
strating an overall increased risk of opportunistic leishmania-
sis under TNF-alpha therapy. Even though the drastic
increase in reports of opportunistic leishmaniasis in 2009 and
2010, preceded by a doubling of anti-TNF prescriptions from
2006 to 2009, suggests such an association, it is important to
note that opportunistic leishmaniasis also occurs under tradi-
tional immunosuppressive regimens. The observed rise in
case reports might therefore be a mere reflection of the lar-
ger interest in adverse events related to a new class of com-
pounds. Time of immunosuppressive therapy prior to onset
of opportunistic infection should be less likely to be subject
to such reporting bias. We found that the mean duration of
anti-TNF therapy before onset of leishmaniasis was
17.5 months, compared with 74 months in patients treated
with traditional immunosuppressive regimens alone [8], thus
adding support to the hypothesis that TNF-alpha antagonists
might indeed increase the risk of leishmaniasis more than
traditional immunosuppressants.
In summary, this study provides first evidence of a lower
risk of opportunistic leishmaniasis in patients treated with
etanercept compared with subjects receiving anti-TNF-alpha
monoclonal antibodies. This finding has implications for pre-
vention of opportunistic leishmaniasis, considering the crucial
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role of host immunity in controlling this infection, the
increasing use of TNF-alpha antagonists and the high preva-
lence of latent infections in endemic areas of Europe [21].
Moreover, an estimated 12 million individuals worldwide are
infected with Leishmania [43] and many endemic regions
include countries with emerging economies. TNF-alpha
antagonists may become more widely accessible there in the
future, which emphasizes the need to quantify the potential
impact of this finding on a global scale.
More detailed post-authorization safety studies and a
European adverse events reporting registry are needed to
provide definitive evidence of an increased risk of opportu-
nistic leishmaniasis associated with anti-TNF-alpha therapy,
overall and depending on the antagonist used. Future
research should evaluate the predictive value of serological
or molecular testing for latent Leishmania infection before
initiation of therapy. Meanwhile, in the absence of better evi-
dence, clinicians may want to consider our observations,
which suggest that etanercept should be favoured over anti-
TNF monoclonal antibodies in individuals living in or visiting
areas endemic for leishmaniasis.
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